<scp>First‐in‐human</scp> development of a pharmacodynamic biomarker for <scp> PAC <sub>1</sub> </scp> receptor antagonists using intradermal injections of maxadilan-Reference-Cited by-同舟云学术

First‐in‐human development of a pharmacodynamic biomarker for PAC ₁ receptor antagonists using intradermal injections of maxadilan

Published:2022-05-27 Issue:8 Volume:15 Page:1968-1977
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Marynissen Heleen¹^ORCID,Buntinx Linde²,Bamps Dorien¹^ORCID,Depre Marleen¹,Ampe Els¹,Van Hecken Anne¹,Gabriel Kristin³,Sands Steve⁴,Vargas Gabriel⁵,de Hoon Jan¹

Affiliation:

1. Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium

2. Anima Research Center Alken Belgium

3. Spark Therapeutics, Member of the Roche Group Philadelphia Pennsylvania USA

4. Amgen Inc. Thousand Oaks California USA

5. CuraSen Therapeutics San Carlos California USA

Funder

Amgen

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13309

Reference34 articles.

1. Migraine: epidemiology and systems of care

2. Migraine prevalence, disease burden, and the need for preventive therapy

3. Migraine: integrated approaches to clinical management and emerging treatments

4. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

5. Ubrogepant in the Acute Management of Migraine: A Narrative Review

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The biotechnological potential of proteases from hematophagous arthropod vectors;Frontiers in Cellular and Infection Microbiology;2023-10-26